Genprex Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
GNPX Nasdaq 8731 https://www.genprex.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genprex Inc

Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies - Mar 23rd, 2023 11:30 am
Genprex to Present at Bioprocessing Summit Conference - Mar 13th, 2023 11:30 am
Genprex to Participate in March Investor and Industry Conferences - Mar 8th, 2023 12:30 pm
Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor - Feb 27th, 2023 1:30 pm
Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023 - Feb 23rd, 2023 12:00 pm
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh - Jan 5th, 2023 12:00 pm
Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes - Jan 4th, 2023 12:00 pm
Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh - Dec 15th, 2022 12:00 pm
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer - Dec 14th, 2022 12:00 pm
Genprex to Present at Upcoming December Investor Conference - Dec 2nd, 2022 1:15 pm
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate - Oct 24th, 2022 1:45 pm
Genprex to Present at Upcoming October Investor and Industry Conferences - Oct 7th, 2022 11:45 am
Genprex to Present at Upcoming September Investor Conference - Sep 8th, 2022 12:15 pm
Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers - Aug 16th, 2022 11:00 am
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer - Aug 15th, 2022 11:00 am
Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit - Jul 13th, 2022 11:00 am
Genprex to Present at Upcoming June Investor Conferences - Jun 2nd, 2022 11:00 am
Genprex to Present at Upcoming Investor Conference in May 2022 - May 19th, 2022 12:15 pm
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation - May 17th, 2022 12:23 pm
Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference - May 9th, 2022 12:15 pm